ChemoMetec and Roche Diagnostics partner to integrate cell counting and bioprocess monitoring systems
- nuaxia
- 5 days ago
- 2 min read
The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.
ChemoMetec and Roche Diagnostics have entered a collaboration agreement to develop a connectivity solution linking ChemoMetec’s XcytoMatic 30 (XM30) cell counting analyser with Roche’s Cedex Bio Analyzer, following a letter of intent signed in February 2026.
The partnership aims to integrate complementary cell-counting and bioprocess-analysis technologies while allowing both companies to continue selling their respective instruments independently.
Field | Content |
Alert Type | Deal |
Companies | ChemoMetec; Roche Diagnostics |
Deal Type | Technology development and commercial collaboration |
Asset or Company | Connectivity solution linking ChemoMetec’s XcytoMatic 30 (XM30) cell counting analyser with Roche’s Cedex Bio Analyzer |
Technology or Modality | Cell counting and bioprocess monitoring technology |
Deal Value | Financial terms have not been disclosed. |
Geography | Global |
What Happened | On 10 August 2026, ChemoMetec and Roche Diagnostics entered a collaboration agreement covering development and subsequent commercialisation of a connection kit between Roche’s Cedex Bio Analyzer and ChemoMetec’s XcytoMatic 30 cell counting analyser. Roche will design the connection kit and undertake verification and validation, with the planned hardware and software connectivity intended to integrate the two systems. The companies will jointly promote the combined solution, while each will remain the sole seller of its own instrument. The agreement follows a letter of intent announced on 4 February 2026. (GlobeNewswire) |
Why It Matters | The agreement brings together two complementary measurements used in bioprocess monitoring: ChemoMetec’s automated cell-counting technology and Roche’s bioprocess analyser. Successful integration could provide pharmaceutical and biotechnology customers with a more connected workflow for monitoring cell cultures during biopharmaceutical development and manufacturing, although the companies have not disclosed commercial targets or a launch timetable. (GlobeNewswire) |
Supporting Context | ChemoMetec and Roche first announced their intention to explore the collaboration in February 2026, identifying connectivity between the XM30 and Cedex Bio Analyzer as the initial project. The new agreement moves that relationship from an exploratory letter of intent to a defined development and commercial collaboration. (Chemometec) |
Strategic Rationale | ChemoMetec gains a route to integrate its cell-counting technology with an established Roche bioprocess platform and jointly promote the combined solution, while Roche adds automated cell-counting connectivity to the Cedex Bio Analyzer workflow without either company transferring ownership of its underlying instrument. (GlobeNewswire) |
Potential Impact | If successfully developed and validated, the connectivity solution could support more integrated bioprocess monitoring workflows for pharmaceutical and biotechnology manufacturers. Its commercial impact will depend on completion of development, validation and customer adoption. |
Key Takeaway | The agreement converts ChemoMetec and Roche’s February 2026 exploratory partnership into a formal collaboration to develop and jointly promote an integrated bioprocess monitoring solution. |
What to Watch | Completion of Roche’s development, verification and validation work, details of commercial availability and implementation of the companies’ joint go-to-market strategy. (GlobeNewswire) |
Primary Source | |
Relevant Date | 10 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments